Today in New Delhi, India
Apr 21, 2019-Sunday
New Delhi
  • Humidity
  • Wind

Breakthrough: This new pill might just treat diabetes and help you lose weight too

UK researchers have developed a new pill which will greatly help diabetic patients. It is believed this is the first type 2 diabetes pill to instigate weight loss.

fitness Updated: Oct 18, 2017 11:56 IST
Asian News International, Washington DC
Diabetes,Type 2 diabetes,Weight loss
Diabetes is affecting more and more Indians each year. (Shutterstock)

The silent and deadly disease diabetes is on the rise in India. While a low calorie diet might reverse diabetes, a team of researchers has recently created a new pill that might be a breakthrough. It can significantly improve the health of people with diabetes and help to shed those extra kilos from their waistlines. The findings indicated that among patients with type 2 diabetes, the drug semaglutide taken by pill resulted in better glycemic control than placebo over 26 weeks.

The results from 632 patients indicated that semaglutide allowed 71% of them to shed pounds. It is believed this is the first type 2 diabetes pill to instigate weight loss. Although several type 2 diabetes treatments are available, therapy selection involves consideration of the risks of adverse effects such as hypoglycemia (low blood sugar) or weight gain and complexity of treatment.

The oral formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonists (a class of drugs used for the treatment of type 2 diabetes), may improve acceptance and adherence for some patients compared with the injectable formulation of GLP-1 receptor agonists.

Melanie Davies from the University of Leicester, United Kingdom, and colleagues randomly assigned 632 patients with Type-2 diabetes and insufficient glycemic control to different doses and dose escalation of once-daily oral semaglutide; oral placebo; or once-weekly semaglutide by injection (subcutaneous) for 26 weeks.Clinically relevant (five percent or more) weight loss was achieved in up to 71 percent of patients receiving oral semaglutide. The research is published in The Jama Network Journals.

Follow @htlifeandstyle for more

First Published: Oct 18, 2017 11:55 IST